中国医师杂志
中國醫師雜誌
중국의사잡지
JOURNAL OF CHINESE PHYSICIAN
2012年
11期
1490-1492
,共3页
洛沙坦/治疗应用%庚酸类/治疗应用%吡咯类/治疗应用%糖尿病肾病/药物疗法
洛沙坦/治療應用%庚痠類/治療應用%吡咯類/治療應用%糖尿病腎病/藥物療法
락사탄/치료응용%경산류/치료응용%필각류/치료응용%당뇨병신병/약물요법
Losartan/therapeutic use%Heptanoic acids/therapeutic use%Pyrroles/therapeutic use%Diabetic nephropathies/drug therapy
目的 探讨氯沙坦联合阿托伐他汀治疗糖尿病肾病(DN)的临床效果.方法 将122例DN患者随机分为两组,对照组61例给予常规治疗加氯沙坦,观察组61例在对照组的基础上加用阿托伐他汀治疗,两组疗程均为12周,治疗12周后检测两组患者的收缩压(SBP)、舒张压(DBP)、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、空腹血糖(FBG)、尿微量白蛋白排泄率(UAER)、血肌酐(Scr)、糖化血红蛋白(HbAIc).结果 观察组总有效率为93.44%,对照组为75.41%,两组相比较差异有统计学意义(x2=7.54,P<0.01);两组患者治疗12周后的SBP、DBP与治疗前比较均有所下降,差异有统计学意义(SBP:t=16.25,17.34,P<0.01;DBP:t=18.10,17.04,P<0.01);对照组FBG、UAER、HbAlc均较治疗前明显降低(P<0.05),观察组的TG、TC、LDL-C、HDL-C、FBG、UAER、Scr、HbAlc均较治疗前显著降低(P<0.05),观察组的TG、TC、UAER、Scr明显低于对照组(P<0.05).结论 氯沙坦联合阿托伐他汀治疗DN较常规治疗加氯沙坦在减少尿微量白蛋白作用方面更具优势,且能加强保护肾功能的作用.
目的 探討氯沙坦聯閤阿託伐他汀治療糖尿病腎病(DN)的臨床效果.方法 將122例DN患者隨機分為兩組,對照組61例給予常規治療加氯沙坦,觀察組61例在對照組的基礎上加用阿託伐他汀治療,兩組療程均為12週,治療12週後檢測兩組患者的收縮壓(SBP)、舒張壓(DBP)、甘油三酯(TG)、總膽固醇(TC)、低密度脂蛋白膽固醇(LDL-C)、高密度脂蛋白膽固醇(HDL-C)、空腹血糖(FBG)、尿微量白蛋白排洩率(UAER)、血肌酐(Scr)、糖化血紅蛋白(HbAIc).結果 觀察組總有效率為93.44%,對照組為75.41%,兩組相比較差異有統計學意義(x2=7.54,P<0.01);兩組患者治療12週後的SBP、DBP與治療前比較均有所下降,差異有統計學意義(SBP:t=16.25,17.34,P<0.01;DBP:t=18.10,17.04,P<0.01);對照組FBG、UAER、HbAlc均較治療前明顯降低(P<0.05),觀察組的TG、TC、LDL-C、HDL-C、FBG、UAER、Scr、HbAlc均較治療前顯著降低(P<0.05),觀察組的TG、TC、UAER、Scr明顯低于對照組(P<0.05).結論 氯沙坦聯閤阿託伐他汀治療DN較常規治療加氯沙坦在減少尿微量白蛋白作用方麵更具優勢,且能加彊保護腎功能的作用.
목적 탐토록사탄연합아탁벌타정치료당뇨병신병(DN)적림상효과.방법 장122례DN환자수궤분위량조,대조조61례급여상규치료가록사탄,관찰조61례재대조조적기출상가용아탁벌타정치료,량조료정균위12주,치료12주후검측량조환자적수축압(SBP)、서장압(DBP)、감유삼지(TG)、총담고순(TC)、저밀도지단백담고순(LDL-C)、고밀도지단백담고순(HDL-C)、공복혈당(FBG)、뇨미량백단백배설솔(UAER)、혈기항(Scr)、당화혈홍단백(HbAIc).결과 관찰조총유효솔위93.44%,대조조위75.41%,량조상비교차이유통계학의의(x2=7.54,P<0.01);량조환자치료12주후적SBP、DBP여치료전비교균유소하강,차이유통계학의의(SBP:t=16.25,17.34,P<0.01;DBP:t=18.10,17.04,P<0.01);대조조FBG、UAER、HbAlc균교치료전명현강저(P<0.05),관찰조적TG、TC、LDL-C、HDL-C、FBG、UAER、Scr、HbAlc균교치료전현저강저(P<0.05),관찰조적TG、TC、UAER、Scr명현저우대조조(P<0.05).결론 록사탄연합아탁벌타정치료DN교상규치료가록사탄재감소뇨미량백단백작용방면경구우세,차능가강보호신공능적작용.
Objective To investigate the therapeutic effects of the losartan combined with atorvastatin on patients with diabetic nephropathy (DN).Methods 122 patients with DN were randomly divided into two groups,61 cases in the control group were received conventional therapy and added the losartan,61 cases in the observation group were treated by atorvastatin on the basis of the control group.The treatment time was 12weeks for each group.After 12 weeks,the systolic blood pressure (SBP),diastolic blood pressure (DBP),triglycerides (TG),total cholesterol (TC),low-density lipoprotein cholesterol (LDL-C),high density lipoprotein cholesterol (HDL-C),fasting blood glucose (FBG),urinary albumin excretion rate (UAER),serum creatinine (Scr),and glycosylated hemoglobin (HbAIc) were measured.Results The total effective rate was 93.44% in the observation group,and 75.41% in the control group,with a statistically significant difference between two groups (x2 =7.54,P < 0.01).After 12 weeks,the SBP and DBP were all changed more than before,DBP decreased more significantly (SBP:t =16.25,17.34,P <0.01 ;DBP:t =18.10,17.04,P <0.01); FBG,UAER,and HbAlc in the control group were significantly reduced (P < 0.05) ; the TG,TC,LDL,-C HDL,-CFBG,UAER,Scr,and HbAlc of the observed group were significantly reduced more,too.TG,TC,UAER,and Scr of the observed group were significantly lower than the control group (P < 0.05).Conclusions The losartan combined with atorvastatin that were used to treat patients with DN can reduce the urine albumin and protect the renal function.